Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Clinical Implications of Tucatinib Approval in Europe

April 14th 2021

Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.

Dr. Hassan on the Rationale for Examining Talazoparib Plus Carboplatin in TNBC

April 14th 2021

Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis

April 13th 2021

The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.

Multi-Omics Approach to Personalized Therapy Shows Feasibility in Metastatic Breast Cancer

April 13th 2021

A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.

Talazoparib Plus Carboplatin Induces Synergistic Activity in Multiple TNBC Cell Lines

April 12th 2021

The combination of the PARP inhibitor talazoparib and carboplatin demonstrated synergistic activity in 7 cell lines of triple-negative breast cancer, with greater DNA damage and cell death observed in PARP inhibitor–resistant cell lines and at lower concentrations of talazoparib when combined with carboplatin.

Future Is Wide Open for HER2+ Breast Cancer

April 12th 2021

As longer-term follow-up data become available for several agents approved for HER2-positive metastatic breast cancer, investigators are looking closely at the characteristics of patients enrolled in those clinical trials to determine appropriate treatment strategies in the third-line setting and beyond.

Neratinib Plus Fulvestrant Fails to Meet Efficacy Threshold in ER+ Metastatic Breast Cancer

April 12th 2021

Neratinib in combination with fulvestrant was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, although the clinical benefit rate did not meet the predefined efficacy criteria.

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

April 11th 2021

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid Biopsies

April 10th 2021

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Research Efforts in HER2+ Breast Cancer Pick Up Speed Despite COVID-19

April 9th 2021

Jane L. Meisel, MD, discusses sequencing questions, tucatinib combinations under exploration, and emerging strategies for use in the treatment of patients with HER2-positive breast cancer.

FDA Grants Regular Approval to Sacituzumab Govitecan for TNBC

April 7th 2021

The FDA has granted a regular approval to sacituzumab govitecan for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have previously received 2 or more systemic therapies, at least 1 of them for metastatic disease.

Matsen Spotlights Best Practices for Breast Cancer Surgery Amidst the COVID-19 Crisis

April 7th 2021

The coronavirus disease 2019 pandemic had a tremendous impact on the surgical care of patients with breast cancer; practice patterns needed to be rapidly adjusted to continue to safely provide care during a time when resources were very limited.

Real-World Experience With Tucatinib in Germany and France

April 7th 2021

An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.

Favorable Safety Profile of Tucatinib for Metastatic HER2+ BC

April 7th 2021

Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.

European Commission Approval of Tucatinib in HER2+ BC

April 7th 2021

Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.

Dr. Meisel on Managing Toxicities Associated with T-DM1 in HER2+ Breast Cancer

April 6th 2021

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Bhave Spotlights Breakthroughs Made With Immunotherapy Combinations in TNBC

April 6th 2021

Chemoimmunotherapy has become the standard of care for the frontline treatment of patients with PD-L1–positive, locally advanced or metastatic triple-negative breast cancer. However, understanding which patients will derive the most benefit from the approach is in need of further exploration

Longer Follow-Up Is Imperative With Adjuvant CDK4/6 Inhibitors in ER+ Breast Cancer

April 5th 2021

Optimal patient selection and duration of therapy are the 2 biggest areas to tackle regarding CDK4/6 inhibition in the adjuvant setting of estrogen receptor–positive breast cancer.